tacrine and edrophonium bromide

tacrine has been researched along with edrophonium bromide in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (42.86)18.2507
2000's3 (42.86)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bier, J; Cho, SJ; Garsia, ML; Tropsha, A1
Karplus, M; So, SS1
Andrisano, V; Bolognesi, ML; Budriesi, R; Cavalli, A; Cavrini, V; Melchiorre, C; Recanatini, M; Rosini, M; Tumiatti, V1
Andrisano, V; Bartolini, M; Bidon-Chanal, A; de Austria, C; del Monte-Millán, M; Dorronsoro, I; García-Palomero, E; Luque, FJ; Martínez, A; Medina, M; Muñoz-Ruiz, P; Orozco, M; Rubio, L; Usán, P; Valenzuela, R1
Lombardo, F; Obach, RS; Waters, NJ1
Agnusdei, M; Belinskaya, T; Borriello, M; Brindisi, M; Butini, S; Campiani, G; Catalanotti, B; Fattorusso, C; Fiorini, I; Gemma, S; Nacci, V; Novellino, E; Panico, A; Persico, M; Ros, S; Saxena, A1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1

Other Studies

7 other study(ies) available for tacrine and edrophonium bromide

ArticleYear
Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors.
    Journal of medicinal chemistry, 1996, Dec-20, Volume: 39, Issue:26

    Topics: Acetylcholinesterase; Binding Sites; Cholinesterase Inhibitors; Molecular Structure

1996
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.
    Journal of medicinal chemistry, 1997, Dec-19, Volume: 40, Issue:26

    Topics: Cholinesterase Inhibitors; Dopamine beta-Hydroxylase; Drug Design; Enzyme Inhibitors; GABA-A Receptor Agonists; GABA-A Receptor Antagonists; Molecular Conformation; Molecular Structure; Neural Networks, Computer; Phosphorylases; Receptors, Aryl Hydrocarbon; Static Electricity; Structure-Activity Relationship

1997
Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease.
    Journal of medicinal chemistry, 1998, Oct-22, Volume: 41, Issue:22

    Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Erythrocytes; Humans; Kinetics; Ligands; Models, Molecular; Polyamines; Receptor, Muscarinic M2; Receptors, Muscarinic; Structure-Activity Relationship

1998
Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
    Journal of medicinal chemistry, 2005, Nov-17, Volume: 48, Issue:23

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Butyrylcholinesterase; Cattle; Cell Line, Tumor; Cholinesterase Inhibitors; Dimerization; Drug Design; Erythrocytes; Fluorometry; Humans; Models, Molecular; Nootropic Agents; Protein Binding; Structure-Activity Relationship; Tacrine

2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
    Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11

    Topics: Acetylcholinesterase; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Computational Biology; Crystallography, X-Ray; Drug Design; Humans; Models, Molecular; Protein Conformation; Structure-Activity Relationship; Tacrine

2008
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011